Effect of Food on the Pharmacokinetic and Pharmacodynamic Profiles of Hetrombopag in Healthy Volunteers

  • Thrombopoietin receptor agonists: eltrombopag and romiplostim for the treatment of chronic immune thrombocytopenia purpura.

    Clin J Oncol Nurs. 2019; 23: 212-216

    • Fattizzo B.
    • Levati G.
    • Cassin R.
    • Barcellini W.

    Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation.

    Drugs. 2019; 79: 1305-1319

    • Portielje J.E.
    • Westendorp R.G.
    • Kluin-Nelemans H.C.
    • Brand A.

    Morbidity and mortality in adults with idiopathic thrombocytopenic purpura.

    Blood. 2001; 97: 2549-2554

    • Bussel J.B.
    • Cheng G.
    • Saleh M.N.
    • et al.

    Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

    N Engl J Med. 2007; 357: 2237-2247

    • Harker L.A.
    • Roskos L.K.
    • Marzec U.M.
    • et al.

    Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers.

    Blood. 2000; 95: 2514-2522

    • Xie C.
    • Zhao H.
    • Bao X.
    • Fu H.
    • Lou L.

    Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist.

    J Cel Mol Med. 2018; 22: 5367-5377

  • Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia.

    Core Evid. 2006; 1: 221-231

    • Zheng L.
    • Liang M.Z.
    • Zeng X.L.
    • et al.

    Safety, pharmacokinetics and pharmacodynamics of hetrombopag olamine, a novel TPO-R agonist, in healthy individuals.

    Basic Clin Pharmacol Toxicol. 2017; 121: 414-422

    • Zhang J.
    • Thapar M.
    • Farrell C.
    • Wire M.B.

    Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.

    Pharm Res. 2015; 32: 2015-2028

    • Wählby U.
    • Jonsson E.N.
    • Karlsson M.O.

    Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.

    AAPS PharmSci. 2002; 4: E27

    • Katsube T.
    • Shimizu R.
    • Fukuhara T.
    • Kano T.
    • Wajima T.

    Pharmacokinetic/pharmacodynamic modelling and simulation of lusutrombopag, a novel thrombopoietin receptor agonist, for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures.

    Clin Pharmacokinet. 2019; 58: 1469-1482

    • Farrell C.
    • Hayes S.C.
    • Wire M.
    • Zhang J.

    Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease.

    Br J Clin Pharmacol. 2014; 77: 532-544

    • Hayes S.
    • Mudd Jr., P.N.
    • Ouellet D.
    • Johnson B.M.
    • Williams D.
    • Gibiansky E.

    Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.

    Cancer Chemother Pharmacol. 2013; 71: 1507-1520

    • Hayes S.
    • Ouellet D.
    • Zhang J.
    • Wire M.B.
    • Gibiansky E.

    Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing.

    J Clin Pharmacol. 2011; 51: 1403-1417

    • Wu K.
    • Thapar M.
    • Farrell C.
    • et al.

    Population pharmacokinetic and pharmacodynamic modeling and effects on platelet counts of different dosages of eltrombopag in Chinese patients with chronic primary immune thrombocytopenia.

    Clin Ther. 2015; 37: 1382-1395

    • Krishna G.
    • Kisicki J.C.
    • Olsen S.
    • Grasela D.M.
    • Wang Z.

    Effect of an aluminum- and magnesium-containing antacid on the bioavailability of garenoxacin in healthy volunteers.

    Pharmacotherapy. 2007; 27: 963-969

    • Stass H.
    • Böttcher M.F.
    • Ochmann K.

    Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.

    Clin Pharmacokinet. 2001; 40: 39-48

    • Wire M.B.
    • Bruce J.
    • Gauvin J.
    • et al.

    A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.

    Clin Ther. 2012; 34: 699-709

    • Williams D.D.
    • Peng B.
    • Bailey C.K.
    • et al.

    Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.

    Clin Ther. 2009; 31: 764-776

  • Noncompartmental vs. compartmental analysis: some bases for choice.

    Am J Physiol. 1982; 243: R1-R6

  • Ways to fit a PK model with some data below the quantification limit.

    J Pharmacokinet Pharmacodyn. 2001; 28: 481-504

    • Gibiansky E.
    • Zhang J.
    • Williams D.
    • Wang Z.
    • Ouellet D.

    Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.

    J Clin Pharmacol. 2011; 51: 842-856

    • Yang G.
    • Huang R.
    • Yang S.
    • et al.

    Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers.

    Br J Clin Pharmacol. 2020; 86: 1528-1536

    • Machlus K.R.
    • Italiano Jr., J.E.

    The incredible journey: from megakaryocyte development to platelet formation.

    J Cel Biol. 2013; 201: 785-796

    • Landersdorfer C.B.
    • He Y.L.
    • Jusko W.J.

    Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.

    Br J Clin Pharmacol. 2012; 73: 391-401

    • Retlich S.
    • Duval V.
    • Graefe-Mody U.
    • Jaehde U.
    • Staab A.

    Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients.

    J Clin Pharmacol. 2010; 50: 873-885

  • Comments are closed.